Page 308 - 北京京煤集团总医院第十届·2022学术年会论文集

北京京煤集团总医院 第十届·2022 学术年会论文集

evaluate the severity of tinnitus and the degree of disability. The tinnitus loudness before and after

treatment was detected in the two groups, the clinical efficacy was evaluated, and related adverse

reactions were statistically analyzed. Results There was no significant difference in THI score and
tinnitus loudness between the two groups before treatment (P>0.05). After 4 weeks of treatment,

the THI score and tinnitus loudness of the two groups were significantly decreased compared with
before treatment (P< 0.05), but there was no significant difference between the two groups (P>

0.05). Before treatment, there was no significant difference in the degree of tinnitus disability

between the two groups (P> 0.05). After 4 weeks of treatment, the slight and mild disabilities were

increased in both groups, while the moderate, severe and extremely severe disabilities were

decreased. After treatment, the proportion of grade 1 was significantly increased in both groups (P

<0.05), and the proportion of grade 3 was significantly decreased in both groups (P< 0.05). However,

there was no significant difference between groups (P> 0.05). There was no significant difference

in the total effective rate between the two groups (P> 0.05). The incidence of vertigo and local pain

in the tympanic group was significantly higher than that in the retroauricular group (P<0.05).

Conclusion Both the retroauricular and tympanic injections of methylprednisolone can improve the

severity and disability of tinnitus, reduce the tinnitus loudness, and have the same effect. However,
there are fewer adverse reactions related to the retroauricular injection and the overall safety is better

than tympanic injection.
Keywords: Chronic primary tinnitus; methylprednisolone; retroauricular injection; tympanic

injection; clinical efficacy; safety

耳鸣是指在无相应的外界声源或电刺激，而主观上在耳内或颅内有声音感觉 。我们通
[1]
常所指的耳鸣为原发性耳鸣，其病因不明，但可影响患者的情绪状态、睡眠及生活质量，引

起躯体及心理等不适 [2-3] 。根据病程的长短可将耳鸣分为急性期和慢性期,通常将耳鸣持续存

[4]
在>6 个月作为慢性耳鸣的标准 。慢性原发性耳鸣缺乏根治手段，但可通过药物治疗、掩蔽
治疗、声治疗、习服治疗、心理学治疗、电磁刺激治疗和针灸治疗等多种方法减轻耳鸣症状

[5-6] 。目前药物治疗仍是临床治疗耳鸣的主要手段，糖皮质激素能有效抑制炎症，减轻局部

[7]
水肿，改善内耳微循环，现已成为治疗急性耳鸣的常规用药 ，但其治疗慢性原发性耳鸣是
否有效尚缺乏循证医学证据。鉴于此，本文应用甲强龙局部注射治疗慢性原发性耳鸣以评估

其疗效，且对比分析了耳后注射甲强龙与鼓室注射甲强龙治疗慢性原发性耳鸣的临床疗效及

安全性，旨在为临床治疗慢性原发性耳鸣提供依据。

- 303 -